Back to Alzheimers Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00455000

NCT00455000
Completed Phase 1 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You are male, or a female who is not able to become pregnant (for example, post-menopausal), and you are between 50 and 85 years old
  • You have been diagnosed with probable Alzheimer's disease, confirmed using two specific sets of recognised medical guidelines (confirm with trial site)
  • You scored between 16 and 26 (inclusive) on a standard memory and thinking test called the Mini-Mental State Exam
  • You scored 4 or below on a test that helps doctors check whether thinking problems are related to blood flow in the brain, called the Rosen-Modified Hachinski Ischemia Score (confirm with trial site)

Who may not be able to join:

  • You have been diagnosed with, or have a history of, any other type of dementia or brain-degenerative condition besides Alzheimer's disease
  • You have been diagnosed with, or have a history of, significant problems with blood flow or blood vessels in the brain (such as a stroke)
  • A brain scan (MRI) has shown certain specific findings, such as signs of a stroke, small bleeds in the brain, multiple small fluid-filled spaces, or large areas of changes in the white matter of the brain
  • You have a history of a condition where your immune system attacks your own body (an autoimmune disorder)
  • You have a history of serious allergic reactions, including severe reactions known as anaphylaxis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Pfizer
Registry
clinicaltrials_gov
Start date
1 March 2007
Est. completion
1 September 2009

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇸🇪 Sweden 🇬🇧 United Kingdom

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

To examine the safety, tolerability, and pharmacokinetics of a single dose of PF-04360365 in subjects with mild to moderate AD for one year following dosing.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov